Bavarian Nordic Partners with Serum Institute to Boost Vaccine Supply
Bavarian Nordic A/S (OMX: BAVA), a prominent player in the global vaccine landscape, has recently entered into a significant licensing and manufacturing agreement with Serum Institute of India Pvt. Ltd. This collaboration is centered around the MVA-BN mpox vaccine, aimed at enhancing access and production capacity, particularly for underserved populations.
Enhancing Global Manufacturing Capabilities
This agreement facilitates a technology transfer of the MVA-BN vaccine's current manufacturing process to Serum Institute of India, enabling them to supply the vaccine specifically for the Indian market. As part of this arrangement, SII will acquire the rights to sell and distribute the vaccine, ensuring that those in need can access it during critical times.
Support for Regulatory Approvals
With the agreement in place, Serum Institute will also take the lead in seeking and maintaining regulatory approval for the vaccine within India. This responsibility underscores their commitment to ensuring that the mpox vaccine is readily available to combat future outbreaks.
Collaborative Profit-Sharing Model
What sets this agreement apart is its unique profit-sharing model, which does not involve any upfront or milestone payments. Instead, both Bavarian Nordic and SII will independently manage the costs related to the technology transfer, allowing for a more streamlined approach to vaccine production.
Expanding Access to Vulnerable Populations
Bavarian Nordic is committed to seeking out additional partnerships that can aid in providing equitable access to the MVA-BN vaccine. The focus includes collaborations with local manufacturers in various regions, including Africa, which is vital for ensuring health resources reach those who need them the most.
Voices from Leadership
The CEO of Serum Institute, Adar Poonawalla, highlighted the urgency of their mission: "Our goal has always been to deliver affordable vaccines to people around the world. The recent mpox outbreak stresses the importance of responsive healthcare initiatives, and our partnership with Bavarian Nordic symbolize this mission well. Together, we aim to bolster epidemic preparedness and make life-saving vaccines available to those at risk, particularly in vulnerable communities."
Likewise, Paul Chaplin, President and CEO of Bavarian Nordic, expressed his satisfaction with the agreement, stating, "This partnership marks a pivotal move forward in our efforts to broaden access to the MVA-BN vaccine. Although we currently do not face any manufacturing limitations, it's crucial to build a scalable structure for global production to ensure equitable access for all nations. Collaborating with SII, recognized as the largest vaccine manufacturer globally, enables us to facilitate these goals effectively. We're dedicated to working with international partners to explore more local manufacturing avenues to support vaccine supply."
About Serum Institute of India
Serum Institute of India Pvt. Ltd. has established itself as a leading name in the vaccine manufacturing sector, delivering high-quality and affordable vaccines globally. With its operations spanning over 170 countries, it holds the title of the world's largest vaccine producer by volume. The company's state-of-the-art facility in Pune boasts an annual capacity of four billion doses, which has contributed significantly to global health by saving millions of lives.
About Bavarian Nordic
Bavarian Nordic stands at the forefront of vaccine innovation, committed to enhancing health and saving lives through its extensive portfolio of vaccines. It is recognized as a key provider of mpox and smallpox vaccines, highlighting its pivotal role in public health preparedness. The company continually seeks to improve global health outcomes by expanding access to its vaccines.
Frequently Asked Questions
What is the purpose of Bavarian Nordic's agreement with Serum Institute?
The agreement aims to facilitate the production and distribution of the MVA-BN mpox vaccine, enhancing global access during health emergencies.
How will the partnership impact vaccine availability in India?
Serum Institute will be licensed to sell and distribute the vaccine in India, working towards rapid regulatory approvals to ensure availability.
Is there any upfront payment associated with the agreement?
No, the agreement operates under a profit-sharing model without any associated upfront or milestone payments.
What role does Serum Institute play in this partnership?
Serum Institute is responsible for seeking regulatory approval and managing the manufacturing process for the mpox vaccine in India.
How does Bavarian Nordic ensure equitable access to its vaccines?
Bavarian Nordic seeks additional partnerships globally, especially with local manufacturers, to expand access to its vaccines in underserved regions.
